We have developed a potential tumor -targeting peptide vector ( cRGD -hK ) that is intended to be systemically and repeatedly administered to patients with advanced solid tumors. The peptide vector of 36 L -amino acid residues, CRGDCF( K[ H À ]KKK ) 6 , comprises a tumor -homing RGD motif, a DNA -binding oligolysine, and histidyl residues to facilitate the delivery into the cytosol. Using cytomegalovirus -driven luciferase expression plasmids as a reporter, we tested the transfection efficiency of cRGD -hK in hepatoma and pancreatic cancer cell lines. Transfection with the cRGD -hK / plasmid complexes ( molar ratio 4000:1 ) was inhibited by 50 nM bafilomycin A 1 , an inhibitor of the vacuolar ATPase endosomal proton pump, or 10 M cycloRGDfV, an integrin v3 antagonist, indicating that the three elements of cRGD -hK could function as expected, at least in vitro. In nude mice bearing tumors created by subcutaneous inoculation, luciferase activity in the tumor tissues 48 hours after the injection of the cRGD -hK / plasmid complexes through the tail vein ( 20 g plasmids per mouse ) was significantly higher than that in the lung, kidney, and spleen, but only slightly higher than that in the liver. Although the latter difference was small, we propose a potential nonviral gene therapy for advanced solid tumors through use of the tumor -targeting peptide vector. Cancer Gene Therapy ( 2001 ) 8, 783 -787 
C
ancer gene therapy is primarily intended to eliminate tumor cells either by transduction of therapeutic cytotoxic genes into tumor cells or by enhancing host antitumor immune defenses. Vector development is a crucial factor in achieving success with such gene therapy, and now two major groups of vector systems, viral and nonviral, are being developed. Although viral vector systems are very efficient, some problems have been identified, including immunogenicity, potential risk of unfavorable mutations, and difficulties in manipulation. Conversely, nonviral vector systems, such as cationic liposome-and polymer -DNA complexes, have been developed to circumvent some of these problems, but the inefficacy of the delivery of plasmids from the endocytotic vesicles into the cytosol is one of the primary limiting factors of these systems. The possibly lower level of immunogenicity of nonviral vectors should be favorable for systemic and repetitive administration, which may compensate for their low efficacy and may be required for the treatment of advanced tumors. Given that cytotoxic genes are delivered in vivo, various tumor-targeting strategies are currently being studied with the intent of avoiding toxicity in normal cells. Such strategies include intratumoral injection of oncolytic viruses, the use of tumor-specific promoters to restrict transgene expression in tumor cells, and the introduction of a wild -type p53 gene to induce apoptosis of tumor cells but not normal cells. 1 Alternatively, the question of whether vectors of therapeutic transgenes can be preferentially directed to tumors is also being investigated. Pasqualini et al 2 found that phage displaying an Arg -Gly-Asp (RGD ) -containing peptide with a high affinity for v integrins homed to tumors when injected intravenously into tumor-bearing mice. Other tumor-homing peptides were also isolated by the in vivo selection of phage display libraries. 3 Apart from this, as a receptor-mediated gene delivery vector, Harbottle et al 4 developed a bifunctional linear peptide comprised of an integrin -targeting RGD motif and a DNA -binding moiety consisting of a short stretch of 16 lysine residues. In addition, Midoux et al 5 demonstrated that a peptide containing several histidines is a suitable helper for delivering molecules into the cytosol. Taking advantage of these advances in vector systems for gene therapy, we have developed a novel tumortargeting peptide vector that is intended to be systemically and repeatedly administered to patients with advanced solid tumors.
In the present study, we tested the potency of the peptide vector in vitro and in vivo using luciferase expression plasmids as a reporter. The vector's potential usefulness for tumor targeting may complement other molecular therapeutic approaches for localized and systemic application. 6 -11 
MATERIALS AND METHODS

Materials
The peptide vector of histidylated oligolysine conjugated to a cyclic RGD motif, CRGDCF( K[ H À ]KKK ) 6 ( cRGD -hK; Fig 1 ) , was synthesized and purified by the Peptide Institute ( Osaka, Japan ). The cRGD -hK /plasmid complexes were formed by allowing the mixture of cRGD -hK and plasmids in 1 mM phosphate buffer (pH 7.4) to stand at room temperature for 30 minutes. Transfectam (TF ), a cationic lipopolyamine, was purchased from BioSepra (Marlborough, MA ), and its complexes with plasmids were prepared according to the manufacturer's instruction ( 1.5 L TF to 1 g plasmid DNA ).
Two human hepatoma cell lines (PLC /PRF /5 and HepG2 ) and two human pancreatic cancer cell lines ( Hs700T and MIAPaCa-2) were purchased from the American Type Culture Collection (Rockville, MD ), and were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum ( FBS ) and penicillin -streptomycin -fungison mixture at 378C in a humid atmosphere with 5% CO 2 . All four cell lines were shown to express v integrins by indirect immunofluorescence with the goat antihuman integrin v polyclonal antibody (Q -20; Santa Cruz Biotechnology, Santa Cruz, CA ) and the fluoresceinlabeled rabbit antibody against goat IgG (American Qualex, San Clemente, CA ).
In vitro cell transfection and luciferase assays
Tumor cells were seeded into 12 -well plates (4Â10 4 cells per well) and were grown in 10% FBS medium for 24 hours, and then the complexes of cRGD -hK or TF with luciferase expression plasmids under the control of the human cytomegalovirus ( CMV ) immediate early gene promoter ( Gene Therapy Systems, San Diego, CA ) were added ( 200 ng plasmids /well ) in the absence or presence of 20 M chloroquine, an endosome-disrupting agent (Sigma, St. Louis, MO ). After a further 36 -hour incubation, the cell harvest and luciferase assays were performed by using a PicaGene Luminescence kit ( Toyo Ink, Tokyo, Japan ). The luminescence was recorded for 10 seconds in a MiniLumat LB 9506 luminometer ( Berthold, Wildbach, Germany ), and was expressed in relative light units (RLU ) per microgram of total cellular protein determined by a Coomassie Plus Protein Assay Reagent kit ( Pierce, Rockford, IL ). Bafilomycin A 1 , an inhibitor of the vacuolar ATPase endosomal proton pump ( Sigma ), and cycloRGDfV, an integrin v3 antagonist (Biomol, Plymouth Meeting, PA ), were added simultaneously with the cRGD -hK /plasmid complexes. The results were taken as the mean values from three wells.
In vivo experiments
Tumor-bearing nude mice were made by the subcutaneous inoculation of PLC and MIAPaCa-2 cells ( 10 6 cells ) into the flank of male BALB / c mice at 5 weeks of age ( Clea Japan, Tokyo, Japan ). After 4 weeks, the cRGD -hK / plasmid complexes at the molar ratio of 2000 were injected through the tail vein (20 g plasmids in 100 L buffer per mouse ), and 2 days later, the mice were killed and several organs and tumor tissues were removed. An approximately 3 -to 5 -mm cubic lump was cut from each of the organs or tumor tissues, and was sonicated in the ice -cold cell lysis buffer ( PicaGene Luminescence Kit ) using a Powersonic Model 50 sonicator (Yamato Scientific, Tokyo, Japan ). The resulting sonicate was centrifuged and the supernatant was subjected to the measurements of the luciferase activity and the protein concentration as above.
RESULTS
Influence of molar ratios of cRGD -hK to plasmid on transfection efficiency
As shown in Figure 2 , the luciferase activity in the transfected PLC cells was increased by 36 -hour incubation with the cRGD -hK / plasmid complexes at molar ratios from 1000 to 4000 without chloroquine ( an endosome -disrupting agent), 5, 12 but in the presence of 20 M chloroquine, luciferase activity varied little among the various molar ratios. This suggests that internalization ( endocytosis ) of the complexes may occur efficiently from a lower molar ratio by the association of the RGD motif with the v integrins, but that efficient delivery into the cytosol after the internalization may require a quantity of histidyl residues.
Comparison of transfection efficiency between cRGD -hK and TF
The transfection efficiency of the cRGD -hK / plasmid complexes at the molar ratio of 4000 in the absence or presence of 20 M chloroquine was assessed in comparison with that of TF in PLC and HepG2 cells (Fig 3A ) and in Hs700T and MIAPaCa-2 cells (Fig 3B ) . In the absence of chloroquine, the transfection efficiency of cRGD -hK was similar to that of TF in PLC and Hs700T cells and lower than that of TF in HepG2 and MIAPaCa -2 cells; but in the presence of chloroquine, the transfection efficiency of cRGD -hK was similar to or higher than these other efficiencies. These results indicate that cRGD -hK is relatively effective on endocytosis, but not so on delivery into the cytosol, depending on the cell lines used. Function of histidyl residues and the RGD motif
The effects of 50 nM bafilomycin A 1 , an inhibitor of the vacuolar ATPase endosomal proton pump, 12,13 or 10 M cycloRGDfV, an integrin v3 antagonist, 14, 15 on the transfection of PLC and Hs700T cells with cRGD -hK were assessed by measuring the luciferase activity. As shown in Figure 4 , both bafilomycin A 1 and cycloRGDfV significantly inhibited the luciferase activity both in PLC and Hs700T cells. Accordingly, the transfection efficiency with the cRGD -hK was reduced by the impairment of the acidification in endosomes and by the competition for v integrins.
Distribution of transgene expression in various organs and tumor tissues
The luciferase activity as the transgene expression was measured in various organs and tumor tissues after the systemic administration of the cRGD -hK /plasmid complexes at the molar ratio of 2000 through the tail vein of the tumor-bearing nude mice. As was demonstrated in a comparable in vivo study, in which the luciferase activity was assessed in several organs after the tail vein injection of adenoviral vectors genetically engineered to have an RGD motif in the HI loop, 16 we also detected a very weak luciferase activity and expressed the data of this activity as RLU / mg protein, but not as RLU / g protein. As shown in Figure 5 , the luciferase activity detected in both of the tumor tissues (PLC and MIAPaCa -2 ) was significantly ( P <.05) Figure 3 . Transfection efficiency of the cRGD -hK / plasmid complexes at the molar ratio of 4000 in the absence or presence of 20 M chloroquine was compared with that of Transfectam, a cationic lipopolyamine, in two hepatoma cell lines ( PLC and HepG2; Fig 3A ) and in two pancreatic cancer cell lines ( Hs700T and MIAPaCa -2; Fig 3B ) . Data represent the means ± SEM ( n = 3 -5 ). AOKI, HOSAKA, KAWA, ET AL: TUMOR-TARGETING PEPTIDE VECTOR higher than that in the lung, kidney, and spleen, but only slightly higher than that in the liver.
DISCUSSION
The novel peptide vector described here is comprised of 36 L -amino acid residues, CRGDCF( K[ H À ]KKK ) 6 , and has three elements as in Figure 1 . The first element (i) originates from the tumor-homing peptides isolated through the use of in vivo selection of phage display peptide libraries. 2, 3 Of the three main tumor-homing peptides identified ( CDCRGDCFC, CNGRCVSGCAGRC, and CGSLVRC; three motifs are underlined ), we have utilized the sequence CRGDCF in a cyclic conformation with a disulfide bond, considering affinity rather than specificity (comparison of RGD and NGR ) 3, 17 and the advantage of an RGD motif in a cyclic conformation. 14, 18, 19 The RGD sequence is the crucial determinant of the ligands for v integrins, 2, 20 which are known to be selectively expressed in the human tumor vasculature as well as in many human tumors themselves.
2,21,22
The second and third elements ( ii and iii ) originate from partially histidylated polylysine; a polylysine (average degree of polymerization of 190) in which histidyl residues have been substituted for 38 ± 5% of the " -amino groups has shown the highest gene transfer efficiency. 12 The positively charged polylysine is bound to the negatively charged phosphate backbone of plasmid DNA by electrostatic interactions, and the conformational change of histidine at acidic pH in the endosome lumen favors delivery of the plasmid into the cytosol as with an endosome-disrupting agent. We have constructed a histidylated oligolysine ( 24 lysine residues with six histidyl residues ) that also can form a complex with oligonucleotides such as antisense oligoDNA in a 1:1 molar ratio. 23 In the present study, using the CMV-driven luciferase expression plasmids as a reporter, we tested the in vitro transfection efficiency of cRGD -hK in two hepatoma cell lines ( PLC / PRF /5 and HepG2 ) and two pancreatic cancer cell lines ( Hs700T and MIAPaCa -2 ), which were confirmed to express v integrins by immunofluorescence. When the influence of the molar ratios of cRGD -hK and plasmid was assessed in PLC cells with or without chloroquine (an endosome-disrupting agent ), 5, 12 it was suggested that the RGD motif may cause efficient endocytosis, but a quantity of histidyl residues may be required for efficient delivery into the cytosol. The transfection efficiency in the absence of chloroquine was increased at molar ratios up to 4000; the amount of histidyl residues at the molar ratio of 4000 was roughly comparable to that at the optimal molar ratio of approximately 200 demonstrated by Midoux and Monsigny 12 (oligolysine of 24 lysine residues having 25% of histidyl residues in our study and polylysine of 190 lysine residues having 38% of histidyl residues in their study ). When the transfection efficiency of cRGD -hK at the molar ratio of 4000 was compared with that of TF, a highly efficient vector, 24 in the absence or presence of chloroquine in the four cell lines, cRGD -hK was suggested to be relatively effective on endocytosis but not as effective with respect to delivery into the cytosol, depending on the cell lines used.
To clarify the functional potency of elements of cRGDhK, we assessed the inhibitory effects of bafilomycin A 1 , an inhibitor of the vacuolar ATPase endosomal proton pump that impairs the acidification in endosomes, 12, 13 and cycloRGDfV, an integrin v3 antagonist that competes with the RGD motif, 14, 15 with respect to the in vitro transfection efficiency in PLC and Hs700T cells. That is, the inhibitory effect of bafilomycin A 1 indicates that protonation of the imidazole groups (or a conformational change) of histidyl residues at acidic pH in the endosome lumen favors delivery of the plasmid into the cytosol, 12 whereas the inhibitory effect of cycloRGDfV indicates that the RGD motif is primarily involved in internalization of the complexes through v integrins. Because both bafilomycin A 1 and cycloRGDfV clearly inhibited the luciferase activity ( or the transfection efficiency ), it was demonstrated that the histidyl residues and the RGD motif of the elements of cRGD -hK could function as expected, at least in vitro.
We then tested the in vivo potency of cRGD -hK as a tumor-targeting vector in nude mice bearing tumors by the injection of the cRGD -hK / plasmid complexes at the molar ratio of 2000 through the tail vein. The luciferase activity detected in both of the tumor tissues ( PLC and MIAPaCa -2 ) was significantly higher than that in the lung, kidney, and spleen, but only slightly higher than that in the liver. Although the latter difference was small, such an in vivo distribution of transgene expression suggests the potential usefulness of cRGD -hK as a tumor-targeting peptide vector. In view of the previous reports 3, 17 demonstrating the successful tumor targeting of tumor-homing peptides, the stability of the cRGD -hK /plasmid complexes in the blood stream remains to be certified, or other tumor-homing peptides (CDCRGDCFC and CNGRC ) need to be tested. The tumor-targeting peptide vector is intended for systemic administration, but is thought to be more effective when used for local administration. Therefore, further studies are needed to determine and improve the in vivo potency of functional elements of cRGD -hK, including a comparative study with the RGD oligolysine peptide by Harbottle et al. 4 
